Cognito Therapeutics

This non-invasive neuromodulation device could become a new therapy for Alzheimer’s disease. [Image courtesy of Cognito Therapeutics]Cognito Therapeutics announced today that it enrolled the first patient in a biomarker study within its HOPE pivotal trial.

HOPE evaluates a novel disease-modifying therapy that elicits gamma-frequency brain activity through non-invasive sensory stimulation. Cambridge, Massachusetts-based Cognito aims to slow the progression of Alzheimer’s disease from the comfort of a patient’s home.

This evaluation looks at MRI, cerebrospinal fluid and plasma biomarkers. Cognito believes it could offer key insights into Alzheimer’s progression and may help see earlier predictive responses to Cognito therapy. The company believes it may help to better identify patients and new disease areas that respond best to treatment.

Cognito remains on track to complete the study within projected timelines, with more than 240 pati…

This non-invasive neuromodulation device could become a new therapy for Alzheimer’s disease. [Image courtesy of Cognito Therapeutics]Cognito Therapeutics today announced the publication of MRI imaging data from a study of its non-invasive neurostimulation technology.

The company published MRI imaging data from the Phase 2 OVERTURE study in the Journal of Alzheimer’s Disease. Cambridge, Massachusetts-based Cognito evaluated patients with mild-moderate Alzheimer’s disease receiving one-hour daily treatment.

Patients underwent treatment with the Cognito gamma sensory device for more than six months. They demonstrated reduced white matter atrophy and preserved brain myelin content compared to sham treatment.

MRI treatment effects proved strongest in the entorhinal region, where white matter connections to the hippocampus are known to be involved in learning and memory and are affected in Alzheimer’s. Cognito said these findings fall in line wi…

This non-invasive neuromodulation device could become a new therapy for Alzheimer’s disease. [Image courtesy of Cognito Therapeutics]Cognito Therapeutics announced today that it raised $73 million in a Series B financing round to support its neuromodulation technology.

Cambridge, Massachusetts-based Cognito Therapeutics develops its neurotechnology to treat central nervous system (CNS) diseases. It designed its non-invasive neuromodulation device to deliver proprietary gamma frequency light and sound stimulation. The investigational device is intended to treat Alzheimer’s Disease.

FoundersX Ventures led the funding round with participation from all existing investors. New investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company (Wilson Sonsini’s venture arm) joined the round. Cognito Therapeutics said the Series B brings its total funds raised since inception to $93 million.

In addition to the fi…